Entities / Company
Merck Sharp & Dohme.
company in Madrid, Spain
- Reports this week
- 2
- Active events
- 1
- Connections
- 16
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
FDA approved Par Health's generic drug, which is the generic version of Merck's Janumet® XR.Some support1 report1 development inside
-
Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.Well supported3 reports
-
TD Cowen maintained a Hold rating on Merck Sharp & Dohme on July 4, 2025.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 16, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Glenmark Pharmaceuticals Operational
The two companies are in direct market competition, evidenced by Glenmark launching a drug equivalent to Merck's BRIDION.
History
Events by the month they beganJuly 2026
1 eventJune 2026
3 events- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.
- TD Cowen maintained a Hold rating on Merck Sharp & Dohme on July 4, 2025.